James M. Frates, Chief Financial Officer at Amylyx Pharmaceuticals, Inc. (AMLX), sold 2,658 shares at $36.79 ($96K) on 2023-01-06, disclosed to the SEC on 2023-01-10.
Scheduled sale ($96k) by Chief Financial Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $36.08 | 1,836 | $66K | 68.7% |
| 2 | $36.79 | 822 | $30K | 31.3% |
| Total | $36.30 avg | 2,658 | $96K | 100% |
| Filing → |
| AMLX | SELL | 2026-02-04 | $52K | — | Filing → |
| AMLX | SELL | 2026-01-08 | $37K | — | Filing → |
| AMLX | SELL | 2025-10-02 | $309K | — | Filing → |